Anemia and Inflammation

Interactive Effects of Iron Status and Inflammation on Serum Hepcidin and Erythrocyte Iron Incorporation in Young Women

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03618914

Enrollment

Registered

2018-08-07

Start date

2017-09-15

Completion date

2018-06-30

Last updated

2018-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Iron Deficiency Anemia

Brief summary

During inflammation hepcidin concentrations are increased, leading to a decrease in iron absorption. In iron deficiency anemia hepcidin is suppressed due to the activation of erythropoiesis. Whether inflammation or anemia has the stronger effect on hepcidin is uncertain.

Interventions

BIOLOGICALDultavax and Vaxigrip

All the women got an influenza/DTP vaccine in order to induce acute inflammation

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 49 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI \<27.5kg/m2 * body weight \<70kg * either non-anemic (Hb\>12.5g/dl) or anemic (Hb between 8-12 g/dl and ferritin \<15ng/ml)

Exclusion criteria

* pregnant or lactating * chronic disease * smoking * inflammation defined as CRP\<5mg/L; AGP\<1g/L

Design outcomes

Primary

Measure	Time frame
Fractional and total iron absorption	14 days after the second baseline test meal administration

Secondary

Measure	Time frame	Description
Serum Interleukin 6	up to 36 hours	inflammation
Serum ferritin	up to 36 hours	Iron status
Serum hepcidin	up to 36 hours	—
Serum CRP	up to 36 hours	inflammation
Serum AGP	up to 36 hours	inflammation
Serum transferrin	up to 36 hours	Iron status

Countries

Morocco

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026